StockDrifts LogoStockDrifts

SK Biopharm 326030

Company
에스케이바이오팜SK Biopharm
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-03-30

SK Biopharm (326030) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for SK Biopharm is dated 2024-03-15; the most recent is 2026-03-30. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-03-30SELL시간외매매
SK
--10.9M₩97,400-4.8%₩1.1T ($738.4M)
2025-01-01BUY신규선임
조형래
Cho Hyung-rae
Head of Communication Division4.5K₩108,600+7.9%₩489M ($339K)
2024-03-15SELL증여
정지영
Jeong Ji-young
Head of Finance Division-6.3K₩93,900-24.8%₩592M ($411K)
2024-03-15BUY기타
정지영
Jeong Ji-young
Head of Finance Division6.3K₩93,900+24.8%₩592M ($411K)

Frequently asked questions

Who has been buying SK Biopharm stock?
0 distinct insiders have filed 0 disclosed insider purchases in SK Biopharm (326030), most recently on 2026-03-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does SK Biopharm have?
SK Biopharm has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-03-15 to 2026-03-30.
Where does StockDrifts get SK Biopharm insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for SK Biopharm. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.